Your browser doesn't support javascript.
loading
Can Dopamine Responsiveness Be Predicted in Parkinson's Disease Without an Acute Administration Test?
Betrouni, Nacim; Moreau, Caroline; Rolland, Anne-Sophie; Carrière, Nicolas; Viard, Romain; Lopes, Renaud; Kuchcinski, Gregory; Eusebio, Alexandre; Thobois, Stephane; Hainque, Elodie; Hubsch, Cecile; Rascol, Olivier; Brefel, Christine; Drapier, Sophie; Giordana, Caroline; Durif, Franck; Maltête, David; Guehl, Dominique; Hopes, Lucie; Rouaud, Tiphaine; Jarraya, Bechir; Benatru, Isabelle; Tranchant, Christine; Tir, Melissa; Chupin, Marie; Bardinet, Eric; Defebvre, Luc; Corvol, Jean-Christophe; Devos, David.
Affiliation
  • Betrouni N; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.
  • Moreau C; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.
  • Rolland AS; CHU Lille, Neurology and Movement Disorders Department, Reference Center for Parkinson's Disease, Lille, France; NS-Park French Network.
  • Carrière N; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.
  • Viard R; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.
  • Lopes R; CHU Lille, Neurology and Movement Disorders Department, Reference Center for Parkinson's Disease, Lille, France; NS-Park French Network.
  • Kuchcinski G; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, France; NS-Park French Network.
  • Eusebio A; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.
  • Thobois S; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, France; NS-Park French Network.
  • Hainque E; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.
  • Hubsch C; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille, France; NS-Park French Network.
  • Rascol O; University Lille, INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, LICEND, Lille, France.
  • Brefel C; CHU Lille, Neuroradioloy Department, Lille, France.
  • Drapier S; Aix Marseille Universitë, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, UMR CNRS 7289, Institut de Neuroscience de La Timone, Marseille, France; NS-Park French Network.
  • Giordana C; Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Neurologie C, Bron, France.
  • Durif F; Dëpartement de Neurologie, Hôpital Pitië-Salpêtrière, AP-HP, Paris, France; NS-Park French Network.
  • Maltête D; Fondation Ophtalmologique A de Rothschild, Unitë James Parkinson, Paris, France; NS-Park French Network.
  • Guehl D; University of Toulouse 3, University Hospital of Toulouse, INSERM, Departments of Neuroscience and Clinical Pharmacology, Clinical Investigation Center CIC 1436, Toulouse Parkinson Expert Center, NS-NeuroToul Center of Excellence for Neurodegenerative Disorders (COEN), Toulouse, France; NS-Park Fren
  • Hopes L; University of Toulouse 3, University Hospital of Toulouse, INSERM, Departments of Neuroscience and Clinical Pharmacology, Clinical Investigation Center CIC 1436, Toulouse Parkinson Expert Center, NS-NeuroToul Center of Excellence for Neurodegenerative Disorders (COEN), Toulouse, France; NS-Park Fren
  • Rouaud T; Service de Neurologie, CHU Pont Chaillou, 2 rue Henri le Guilloux, Rennes cedex, France; NS-Park French Network.
  • Jarraya B; Universitë Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand, France; NS-Park French Network.
  • Benatru I; Universitë Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand, France; NS-Park French Network.
  • Tranchant C; Department of Neurology, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France; NS-Park French Network.
  • Tir M; Service d'Explorations Fonctionnelles du Système Nerveux, Institut des Maladies Neurodëgënëratives Cliniques, CHU de Bordeaux, Bordeaux, France; NS-Park French Network.
  • Chupin M; Neurology Department, Nancy University Hospital, Nancy, France; NS-Park French Network.
  • Bardinet E; Clinique Neurologique, Hôpital Guillaume et Renë Laennec, Boulevard Jacques Monod, Nantes Cedex, France; NS-Park French Network.
  • Defebvre L; Movement Disorders Unit, Foch Hospital, Universitë Paris-Saclay (UVSQ), INSERM U992, NeuroSpin, CEA Paris-Saclay, Suresnes, France; NS-Park French Network.
  • Corvol JC; Service de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, Poitiers, France; NS-Park French Network.
  • Devos D; Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Institut de Gënëtique et de Biologie Molëculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Universitë de Strasbourg, Illkirch, France; Fëdëration de Mëdecine Translationnelle de Strasbourg (FMTS), Universitë de S
J Parkinsons Dis ; 12(7): 2179-2190, 2022.
Article de En | MEDLINE | ID: mdl-35871363

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladie de Parkinson / Lévodopa Type d'étude: Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: J Parkinsons Dis Année: 2022 Type de document: Article Pays d'affiliation: France

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladie de Parkinson / Lévodopa Type d'étude: Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: J Parkinsons Dis Année: 2022 Type de document: Article Pays d'affiliation: France